drugset / Trial / NCT05083117
Safety and Efficacy of Inhaled XW001 For Hospitalized COVID-19 Patients Requiring Oxygen Therapy
Phase 2
Withdrawn
Sciwind Biosciences APAC CO Pty. Ltd.
Hangzhou Sciwind Biosciences Co., Ltd. · collabSciwind Biosciences USA Co., Ltd. · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
This is a multiregional, randomized, double-blind, placebo-controlled Phase 2 study in patients with confirmed symptomatic COVID-19, designed to evaluate the safety, tolerability, efficacy, and PK of XW001 (IL-29 analog) inhalation solution. The purpose of this study is to evaluate whether treatment with XW001 reduces the likelihood of worsening disease in patients with severe COVID-19. Hospitalized patients on oxygen therapy by mask or nasal prongs (WHO-OSCI score 4) will be enrolled.
Timeline
- Start
- 2021-10-30
- Primary completion
- 2022-03-10
- Completion
- 2022-04-10
Outcome
Outcome not reported
Stopped (Enrollment): “Difficulty in COVID-19 subject enrollment”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | XW001 | Unknown | 1 mg | Inhaled |